modified an anti-CD39 IgG2 antibody by glycosylation that could deplete CD39-highly expressed immunosuppressive cells by enhancing antibody-dependent cytotoxicity; moreover, the modified anti-CD39 IgG2 and anti-PD-L1 immunotherapy exhibited favorable synergistic effects in mice models of melanoma and colorectal cancer (180). This evidence concerns the gene ENTPD1 and melanoma.